News and
Announcements
Stay up to date on all our news and market announcements.
TruScreen validated as Superior Primary Screening Tool by World's largest Opto-Electronic Cervical Cancer Screening Study
Results of the world's largest ever (n=14,982) study of opto-electronic cervical cancer screening, conducted by Chinese Obstetricians and Gynaecologists Association (COGA), have been published validating TruScreen as a superior primary cervical cancer screening tool over Liquid Based Cytology (LBC) and high-risk Human Papillomavirus (hrHPV) testing.
Clinical study validates TruScreen’s efficacy and safety for pregnant women
Leading Chinese medical publication Family Doctor confirms TruScreen’s efficacy as a cervical cancer screening tool for pregnant women, in a 2,000-patient study conducted at Guilin People’s Hospital.
Published Saudi Arabia study confirmed TruScreen’s high sensitivity and specificity vs pap smear
Published Saudi Arabia study confirms TruScreen’s high sensitivity and specificity compared to pap smear.
Sign up for regular
updates and
announcements.
Can’t see the form?
Email us at marketing@truscreen.com to subscribe